Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of Human Immunoglobulin (pH4) for Intravenous Injection in CIDP
CTR20250745Phase 3Active
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Jun 2025
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of human immunoglobulin (pH 4) for intravenous injection in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Chengdu Rongsheng Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
human immunoglobulin (pH 4) for intravenous injection
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on CTR20250745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250745.